VivoSeq
Other

Cytokine Release Syndrome

3

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Cytokine Release Syndrome is an early-stage landscape with 3 programs across 3 companies. The most active players are Johnson & Johnson, Incyte, Naresh Bumma.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2Incyte logo

Incyte

0 programs

PreclinicalN

Naresh Bumma

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Infliximab

Organon and Co

Talquetamab

Johnson & Johnson

Teclistamab

Johnson & Johnson

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Unknown status2 · 20%
Recruiting2 · 20%
Withdrawn1 · 10%
Enrolling by invitation1 · 10%

Clinical Trials

Trial Activity

10 trials

Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
Recruiting·UUniversity of Pennsylvania·Phase 1·NCT05306080·10 enrolled
Phase 2 Study of Cytokine Release Syndrome Prophylaxis With Infliximab for Teclistamab/Talquetamab Therapy in Patients With Relapsed/Refractory Myeloma
Recruiting·—·Phase 2·NCT07657312·35 enrolled
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
Enrolling by invitation·National Cancer Institute (NCI)·Preclinical·NCT07499128·136 enrolled
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
Completed·UUniversity of Pennsylvania·Phase 1·NCT02906371·80 enrolled
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Completed·Incyte logoIncyte·Phase 2·NCT04071366·112 enrolled
Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.
Completed·FFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia·Phase 2·NCT04348383·156 enrolled
Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation
Completed·HHospital Universitario Dr. Jose E. Gonzalez·Phase 1/2·NCT03533101·30 enrolled
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Withdrawn·JJack Khouri, MD·Phase 2·NCT06352866
Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT04781803·32 enrolled
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Unknown status·—·Phase 1/2·NCT04082910·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)